<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03342638</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD.MOST.2017</org_study_id>
    <nct_id>NCT03342638</nct_id>
  </id_info>
  <brief_title>Maximizing Outcome of Multiple Sclerosis Transplantation</brief_title>
  <acronym>MOST</acronym>
  <official_title>Maximizing Outcome of Multiple Sclerosis Transplantation: &quot;MOST&quot; Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell&#xD;
      transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin&#xD;
      (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases,&#xD;
      it starts as a relapsing-remitting disease with distinct attacks and no symptoms between&#xD;
      flares. Over years or decades, virtually all cases transition into a progressive disease in&#xD;
      which insidious and slow neurologic deterioration occurs with or without acute flares.&#xD;
      Relapsing-remitting disease is often responsive to immune suppressive or modulating&#xD;
      therapies, while immune based therapies are generally ineffective in patients with a&#xD;
      progressive clinical course. This clinical course and response to immune suppression, as well&#xD;
      as neuropathology and neuroimaging studies, suggest that disease progression is associated&#xD;
      with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune&#xD;
      mediated demyelination. Therefore, immune based therapies, in order to be effective, need to&#xD;
      be started early in the disease course while MS is predominantly an immune-mediated and&#xD;
      inflammatory disease. While current immune based therapies delay disability, no intervention&#xD;
      has been proven to prevent progressive disability.The investigators propose a randomized&#xD;
      study of autologous unmanipulated peripheral blood hematopoietic stem cell transplant (HSCT)&#xD;
      comparing two different conditioning regimens: (1) cyclophosphamide and rabbit&#xD;
      anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin&#xD;
      (IVIg).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI Sabbatical&#xD;
  </why_stopped>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Rate of Disease Activity</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as no relapse (defined as acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat or related pseudoexacerbation; supportive confirmation by enhancement on MRI is preferred), no disease progression (defined as a 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease process), and no new or enhancing lesions on MRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVIg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Potent immunosuppressive agent; an alkylating agent</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Medication used to decrease the risk of hemorrhagic cystitis prophylaxis</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rATG</intervention_name>
    <description>A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Steroid</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IVIg</intervention_name>
    <description>Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).</description>
    <arm_group_label>IVIg Arm</arm_group_label>
    <other_name>Gammagard</other_name>
    <other_name>Carimune Nanofiltered (NF)</other_name>
    <other_name>Bivagam</other_name>
    <other_name>Privigen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cells</intervention_name>
    <description>Infusion of participant's own stem cells</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>IVIg Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-58 years&#xD;
&#xD;
          2. Diagnosis of MS using revised McDonald criteria of clinically definite MS (Appendix A)&#xD;
&#xD;
          3. An EDSS score of 2.0 to 6.0 (Appendix B).&#xD;
&#xD;
          4. An EDSS &gt;6.0 may be included if still relapsing-remitting disease and at least two&#xD;
             enhancing lesions on MRI within the last three months&#xD;
&#xD;
          5. Inflammatory disease despite treatment with standard disease modifying therapy (DMT)&#xD;
             including at least 6 months of interferon or Copaxone. Inflammatory disease is defined&#xD;
             based on either MRI (gadolinium enhancing lesion, new T2 lesion) or *steroid-treated&#xD;
             clinical relapses (prescribed by a neurologist)&#xD;
&#xD;
          6. Minimum disease activity required:&#xD;
&#xD;
               1. Failed a first line DMT (Copaxone or Interferon), defined as two or more *steroid&#xD;
                  treated clinical relapses within the last 12 months. A clinical relapse may also&#xD;
                  be evidence of active inflammation on MRI (gadolinium enhancing lesion or new T2&#xD;
                  lesion) in the last 12 months on two MRIs at least three months apart&#xD;
&#xD;
               2. Failed a second or third line MS Drug: Zinbryta (daclizumab), Aubagio&#xD;
                  (teriflunomide), Gilenya (fingolimod), Tecifidera (dimethyl fumarate), Lemtrada&#xD;
                  (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab)&#xD;
                  or IVIg, defined as one *steroid treated clinical relapse within the last 12&#xD;
                  months or evidence of active inflammation on MRI (gadolinium enhancing lesion or&#xD;
                  new T2 lesion) in the last 12 months.&#xD;
&#xD;
               3. Cognitive dysfunction that prevents gainful employment, but competent to comply&#xD;
                  with treatment and informed consent&#xD;
&#xD;
                    -  A steroid-treated relapse will include a relapse that was severe enough to&#xD;
                       justify treatment but due to patient intolerance of steroids, they were&#xD;
                       offered but not used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any adult who is unable to consent (for adults who are cognitively impaired due to MS,&#xD;
             consent may be obtained from the closest living relative or person who has power of&#xD;
             attorney)&#xD;
&#xD;
          2. Individuals under the age of 18 or over the age of 58&#xD;
&#xD;
          3. Diagnosis of Primary Progressive MS, Secondary Progressive MS, or Clinically Isolated&#xD;
             Syndrome (CIS)&#xD;
&#xD;
          4. Pregnant women (positive serum or urine human chorionic gonadotropin (HCG) test)&#xD;
&#xD;
          5. Women who are breastfeeding&#xD;
&#xD;
          6. Prisoners&#xD;
&#xD;
          7. Any illness that in the opinion of the investigators would jeopardize the ability of&#xD;
             the patient to tolerate aggressive chemotherapy&#xD;
&#xD;
          8. Prior history of malignancy except localized basal cell, squamous skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          9. Any prior chemotherapy or radiation therapy (except for cyclophosphamide used to treat&#xD;
             MS disease)&#xD;
&#xD;
         10. History of sickle cell disease (SS), SC disease, coagulopathy, or if actively&#xD;
             receiving anticoagulation therapy&#xD;
&#xD;
         11. History of insulin-dependent diabetes&#xD;
&#xD;
         12. Inability or unwillingness to pursue effective means of birth control from the time of&#xD;
             evaluation for eligibility until 6 months post-transplant. Effective birth control is&#xD;
             defined as (1) abstinence defined as refraining from all acts of vaginal intercourse,&#xD;
             (2) consistent use of birth control pills, (3) injectable birth control methods&#xD;
             (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone&#xD;
             vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of&#xD;
             intercourse, use of diaphragm with contraceptive jelly and/or use of condom with&#xD;
             contraceptive foam&#xD;
&#xD;
         13. Failure to willingly accept or comprehend irreversible sterility as a side effect of&#xD;
             therapy&#xD;
&#xD;
         14. Forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) &lt; 60% of&#xD;
             predicted after bronchodilator therapy (if necessary)&#xD;
&#xD;
         15. Diffusing capacity of the lungs for carbon monoxide (DLCO) &lt; 60% of predicted&#xD;
&#xD;
         16. Resting left ventricular ejection fraction (LVEF) &lt; 50 %&#xD;
&#xD;
         17. Bilirubin &gt; 2.0 mg/dl&#xD;
&#xD;
         18. Serum creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
         19. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins or to iron&#xD;
             compounds/medications&#xD;
&#xD;
         20. Presence of metallic objects implanted in the body that would preclude the ability of&#xD;
             the patient to safely have MRI exams&#xD;
&#xD;
         21. Platelet count &lt; 100,000/ul&#xD;
&#xD;
         22. White blood cell count (WBC) &lt; 1,500 cells/mm3&#xD;
&#xD;
         23. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with&#xD;
             treatment or informed consent impossible&#xD;
&#xD;
         24. Active infection except asymptomatic bacteriuria&#xD;
&#xD;
         25. Use of Tysabri (natalizumab) within the previous six months&#xD;
&#xD;
         26. Use of Gilenya (fingolimod) within the previous three months&#xD;
&#xD;
         27. Use of Tecfidera (dimethyl fumarate) within the previous three months&#xD;
&#xD;
         28. Use of Aubagio (teriflunomide) unless cleared from the body (plasma concentration&#xD;
             &lt;0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a&#xD;
             day for 11 days&#xD;
&#xD;
         29. Use of Lemtrada/Campath (alemtuzumab) within previous 12 months&#xD;
&#xD;
         30. Use of Rituxan (rituximab) or Ocrevus (ocrelizumab) within previous four months&#xD;
&#xD;
         31. Prior treatment with Novantrone (mitoxantrone)&#xD;
&#xD;
         32. Any hereditary neurological disease such as Charcot-Marie-Tooth disease (CMT),&#xD;
             Spinocerebellar ataxia (SCA), or Parkinson's Disease&#xD;
&#xD;
         33. Severe or symptomatic cervical spinal stenosis unless surgically corrected&#xD;
&#xD;
         34. Myocardial infarction within last 12 months; if longer than 12 months, must pass&#xD;
             dobutamine stress test and be cleared by cardiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03342638/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.&#xD;
Cyclophosphamide: Potent immunosuppressive agent; an alkylating agent&#xD;
Mesna: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis&#xD;
rATG: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream&#xD;
Autologous Stem Cells: Infusion of participant's own stem cells</description>
        </group>
        <group group_id="P2">
          <title>IVIg Arm</title>
          <description>Hematopoietic Stem Cell Therapy performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF administered post-transplant.&#xD;
Cyclophosphamide:immunosuppressive agent;alkylating agent&#xD;
Mesna: Prophylaxis decrease for hemorrhagic cystitis&#xD;
rATG: lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes &amp; stem cells and release them into the bloodstream&#xD;
IVIg: Immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).&#xD;
Autologous Stem Cells: Infusion of one's own stem cells</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Arm</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.&#xD;
Cyclophosphamide: Potent immunosuppressive agent; an alkylating agent&#xD;
Mesna: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis&#xD;
rATG: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream&#xD;
Autologous Stem Cells: Infusion of participant's own stem cells</description>
        </group>
        <group group_id="B2">
          <title>IVIg Arm</title>
          <description>Hematopoietic Stem Cell Therapy performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF administered post-transplant.&#xD;
Cyclophosphamide:immunosuppressive agent;alkylating agent&#xD;
Mesna: Prophylaxis decrease for hemorrhagic cystitis&#xD;
rATG: lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes &amp; stem cells and release them into the bloodstream&#xD;
IVIg: Immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).&#xD;
Autologous Stem Cells: Infusion of one's own stem cells</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" lower_limit="23" upper_limit="50"/>
                    <measurement group_id="B2" value="35.3" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="B3" value="35.8" lower_limit="20" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis of Multiple Sclerosis using revised McDonald criteria</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Rate of Disease Activity</title>
        <description>Defined as no relapse (defined as acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat or related pseudoexacerbation; supportive confirmation by enhancement on MRI is preferred), no disease progression (defined as a 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease process), and no new or enhancing lesions on MRI</description>
        <time_frame>5 years</time_frame>
        <population>Study Terminated due to PI taking Sabbatical: Data Not Collected</population>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.&#xD;
Cyclophosphamide: Potent immunosuppressive agent; an alkylating agent&#xD;
Mesna: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis&#xD;
rATG: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream&#xD;
Autologous Stem Cells: Infusion of participant's own stem cells</description>
          </group>
          <group group_id="O2">
            <title>IVIg Arm</title>
            <description>Hematopoietic Stem Cell Therapy performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF administered post-transplant.&#xD;
Cyclophosphamide:immunosuppressive agent;alkylating agent&#xD;
Mesna: Prophylaxis decrease for hemorrhagic cystitis&#xD;
rATG: lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes &amp; stem cells and release them into the bloodstream&#xD;
IVIg: Immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).&#xD;
Autologous Stem Cells: Infusion of one's own stem cells</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Rate of Disease Activity</title>
          <description>Defined as no relapse (defined as acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat or related pseudoexacerbation; supportive confirmation by enhancement on MRI is preferred), no disease progression (defined as a 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease process), and no new or enhancing lesions on MRI</description>
          <population>Study Terminated due to PI taking Sabbatical: Data Not Collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Arm</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.&#xD;
Cyclophosphamide: Potent immunosuppressive agent; an alkylating agent&#xD;
Mesna: Medication used to decrease the risk of hemorrhagic cystitis prophylaxis&#xD;
rATG: A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream&#xD;
Autologous Stem Cells: Infusion of participant's own stem cells</description>
        </group>
        <group group_id="E2">
          <title>IVIg Arm</title>
          <description>Hematopoietic Stem Cell Therapy performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF administered post-transplant.&#xD;
Cyclophosphamide:immunosuppressive agent;alkylating agent&#xD;
Mesna: Prophylaxis decrease for hemorrhagic cystitis&#xD;
rATG: lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens found on the surface of T cells&#xD;
Methylprednisolone: Steroid&#xD;
G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes &amp; stem cells and release them into the bloodstream&#xD;
IVIg: Immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).&#xD;
Autologous Stem Cells: Infusion of one's own stem cells</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>k-quigley@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

